Login
$XENE
$39.05 -$0.21 (0.53%) After hours

$XENE SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
09 Nov 2026 S-8
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026

06 Nov 2026 SCHEDULE 13G/A
06 Nov 2026 SCHEDULE 13G
05 Nov 2026 SCHEDULE 13G/A
16 Oct 2026 Form 4: Kelly Thomas Patrick, Chief Financial Officer

Received 7,500 shares by exercise or conversion

01 Oct 2026 Form 4: Kelly Thomas Patrick, Chief Financial Officer

Bought 15,000 shares ($560K)

01 Oct 2026 Form 4: Mortimer Ian, Director

Bought 30,000 shares ($1.12M)

03 Sep 2026 Form 4: Svoronos Dawn, Director

Received 5,144 shares by exercise or conversion ($41.9K)

31 Aug 2026 Form 4: Kenney Christopher John, Chief Medical Officer

Sold 7,068 shares ($426K)

28 Aug 2026 144
13 Aug 2026 Form 4: Gannon Steven, Director

Sold 10,000 shares ($641K)

13 Aug 2026 144
13 Aug 2026 SCHEDULE 13G/A
07 Aug 2026 SCHEDULE 13G/A
06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

NDA submission for azetukalner on track for Q3 2026 following pre-NDA meeting with FDA

06 Aug 2026 SCHEDULE 13G/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support